Plasmodium Immunotherapy for Brain Tumors Across the Blood-Brain Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for brain tumors, including surgical resection, radiotherapy, and chemotherapy, are limited by their effectiveness and side effects, and immunotherapies such as immune checkpoint inhibitors have not shown significant improvements in survival rates for malignant glioma.
Innovation Solution
A drug utilizing Plasmodium, which activates the immune system by releasing pathogen-related pattern recognition molecules that trigger immune responses, reshaping the tumor microenvironment into an immune-supporting state, and crossing the blood-brain barrier to inhibit tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If surgical resection is used to remove brain tumors, then the tumor mass is reduced, but the risk of brain complications increases and complete removal is difficult for invasive tumors
Solution Approach 1:
The patent extracts the tumor cells from the brain by enhancing immune system recognition and attack capabilities. The immune system naturally targets and eliminates tumor cells through cellular immunity, avoiding the need for surgical extraction that carries risks of brain complications.
Solution Approach 2:
The patent introduces an intermediary mechanism - the immune system - to combat brain tumors. By activating immune cells through intravenous injection and blood-brain barrier disruption, the immune system serves as a mediator that selectively targets tumor cells without directly damaging brain tissue.
2Productivity
If radiotherapy is used to treat brain tumors, then tumor growth is inhibited, but normal brain tissues are damaged and necrosis occurs
Solution Approach 1:
The patent converts the harmful radiation effect into a beneficial immune activation effect. Instead of using radiation that damages both tumor and normal tissues, the patent uses immune activation to target tumor cells selectively, converting the potential harm of aggressive treatment into the benefit of selective tumor destruction through the immune system.
Solution Approach 2:
The patent replaces the mechanical/physical system of radiotherapy with a biological system - the immune system. Instead of using external radiation energy that cannot distinguish between tumor and normal cells, the patent employs living immune cells that can recognize and attack tumor cells specifically through biological recognition mechanisms.
3Productivity
If chemotherapy drugs are used to improve blood-brain barrier permeability, then drug efficacy increases, but side effects such as peritumoral edema and cognitive impairment occur
Solution Approach 1:
The patent uses immune cells as intermediaries to deliver anti-tumor effects. Instead of using chemotherapy drugs that must cross the blood-brain barrier and cause side effects, the patent introduces immune cells that can be activated to attack tumor cells, with the blood-brain barrier temporarily disrupted to enable immune cell entry without requiring high concentrations of toxic chemicals.
Solution Approach 2:
The patent enables the body's own immune system to fight the tumor. By activating the patient's endogenous immune cells through intravenous injection and blood-brain barrier disruption, the treatment harnesses the body's natural defense mechanisms to eliminate tumor cells without introducing external toxic substances that cause side effects.
4Adaptability or versatility
If immunotherapy is used to enhance anti-tumor immunity, then treatment specificity increases, but survival improvement is not achieved for malignant glioma
Solution Approach 1:
The patent performs preliminary action by disrupting the blood-brain barrier before immune cell attack. This preliminary step of barrier disruption enables subsequent immune cells to effectively penetrate and attack tumor cells, addressing the limitation of previous immunotherapies that could not effectively deliver immune cells to brain tumor sites.
Solution Approach 2:
The patent introduces dynamic elements to immunotherapy by combining blood-brain barrier disruption with immune cell activation. The treatment is not static but involves sequential dynamic processes: barrier disruption followed by immune cell infiltration and activation, creating a time-dependent therapeutic effect that overcomes the limitations of static immunotherapy approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The drug significantly inhibits brain tumor growth, prolongs patient lifespan with minimal side effects, and provides new treatment strategies by transforming tumors into effective vaccines.
Implementation Method 1
Pathogen-related pattern recognition molecules (PAMPs) of danger signals released by Plasmodium, including known glycosylphosphatidylinositol anchors (GPI anchors), hemozoin, DNAs of Plasmodium, immunostimulatory nucleic acid motifs and other unknown molecules, can be recognized by pattern recognition receptors (PRRs) of host immune cells.
Implementation Method 2
The drug provided by the present application crosses the blood-brain barrier by fully activating the immune system
Data Source
AI summary
A drug for preventing and/or treating a brain tumor and an application thereof. The drug comprises plasmodium. The drug has significant preventive and/or therapeutic effects on a brain tumor. The drug mainly regulates the immunological functions and inflammation-related factors of the body to break through the blood-brain barrier by fully activating immunocompetence and inhibiting the growth of a brain tumor, thereby extending lifespan.